Determining the Efficacy of a Novel Epstein - Barr Virus (EBV) Peptide Vaccine: A Rabbit Model Approach | Chapter 7 | Research Advances in Microbiology and Biotechnology Vol. 5

 The present study proposed to investigate the Use of Rabbit Model for Efficacy of a Novel Epstein-Barr virus (EBV) Peptide Vaccine. Epstein–Barr virus (EBV or herpes virus) causes infectious herpes virus and is latent in most men. EBV is commonly transmitted by polluted saliva (hence the sobriquet the kissing affliction). The Epstein-Barr virus (Human herpes virus 4) encodes about 80 proteins, 15 of that have at least 90 antigenic epitopes. When many of the immunogenic EBV proteins stimulate T container receptors (TCR), but few interact accompanying B cell receptors (BCR), immunization was raise to protect against them. B container activation and after antibody production have existed linked to at least three wrapper glycoproteins (primarily gp350/220), latency joined membrane proteins (LMPs), and EBNA3/C. The EBV vaccines devised so far fall into two classifications: those preventing any somewhat infection (maybe used for prophylaxis of EBV-mixed malignancies) and those designed for therapeutic purposes (expected used in subjects then infected).The deterrent vaccines protecting against acute ailment (such as IM) contain, usually, the gp350/220 polypeptide (s) encoded for one BLLF1 gene. In contrast, vaccines destined for carcinoma prevention rather contain peptides derived from latency joined nuclear proteins (EBNA 2, 3 and 6) and/or from the oncogenic dormant membrane proteins (LMP1/LMP2A). The advantage of the peptide cure presented here is the reduced probability of the initiation of autoimmune responses, such as the ASIA disease, which may happen in a proportion of immunized inmates.

Author(s) Details:

J. Rajcáni,
Research Triangle Europe Research Center, Mosonmagyaróvár, Hungary.

K. Szenthe,a
Research Triangle Europe Research Center, Mosonmagyaróvár, Hungary.

F. Bánáti,
Research Triangle Europe Research Center, Mosonmagyaróvár, Hungary.

B. Ásványi,
Carlsbad Research Organization, Mosonmagyaróvár, Hungary.

L. Stipkovits,
Carlsbad Research Organization, Mosonmagyaróvár, Hungary.

S. Szathmary,
GalenBio, Hungary.

Please see the link here: https://stm.bookpi.org/RAMB-V5/article/view/10485